Type-II Variation: Waive in-vivo study by providing in-vitro data? [Study As­sess­ment]

posted by qualityassurance – 2024-07-02 13:29 (311 d 14:26 ago) – Posting: # 24054
Views: 2,326

Dear Helmut,

Thank you for the response.

Is it possible to waive in-vivo study if we achieve similar in-vitro dissolution profile in multimedia between test products (BE batch vs new formulation) having different particle size?

Regards,
QA

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,670 registered users;
106 visitors (0 registered, 106 guests [including 10 identified bots]).
Forum time: 03:56 CEST (Europe/Vienna)

We should not speak so that it is possible
for the audience to understand us,
but so that it is impossible
for them to misunderstand us.    Quintilian

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5